George Koliakos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
George Koliakos has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
- Angeliki Cheva
Pathology Department, Faculty of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
4 shared publications - Christos Tsakalidis
Second Department of Neonatology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
3 shared publications - Maria Papaioannou
Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3 shared publications - Orestis Ioannidis
4th Department of Surgery, General Hospital “George Papanikolaou”, Aristotle University of Thessaloniki, 57010 Exochi, Greece
3 shared publications - Panagiota Angeliki Galliou
Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3 shared publications - Anastasia Stoimeni
Aristotle University of Thessaloniki, Greece
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Elsevier in Differentiation
- Vol. 152
Feeder-free expansion and early cardiomyogenic commitment of a human umbilical cord blood-derived cell population with very small embryonic-like stem cell (VSEL)-Like features
- 26 October 2026
- Published by Elsevier in Differentiation
- Vol. 152
Open AccessFeeder-free expansion and early cardiomyogenic commitment of a human umbilical cord blood-derived cell population with very small embryonic-like stem cell (VSEL)-Like features
- Open Access
- 8 September 2026
- Published by Qeios Ltd
Review of: "Reinterpreting Circulating Neuron- and Oligodendrocyte-Derived Extracellular Vesicles for Non-invasive Monitoring of Neonatal Brain Development"
* The manuscript presents L1CAM/CD171-based detection of neuron-derived extracellular vesicles as an established analytical foundation without acknowledging the conflicting literature. Norman M, et al. 2021, L1CAM is not associated with extracellula...
- 8 September 2026
- Published by Qeios Ltd
Open AccessReview of: "Reinterpreting Circulating Neuron- and Oligodendrocyte-Derived Extracellular Vesicles for Non-invasive Monitoring of Neonatal Brain Development"
* The manuscript presents L1CAM/CD171-based detection of neuron-derived extracellular vesicles as an established analytical foundation without acknowledging the conflicting literature. Norman M, et al. 2021, L1CAM is not associated with extracellula...
- Open Access
- 25 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7596
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review
Aging frailty is a multifactorial geriatric syndrome characterized by reduced physiological reserve across multiple interrelated systems, leading to increased vulnerability to adverse health outcomes. Mesenchymal stem cells (MSCs) have emerged as a potential therapeutic intervention due to their immunomodulatory and regenerative properties. This systematic review aimed to evaluate the available clinical evidence regarding the safety and efficacy of MSC administration in individuals with aging frailty. A systematic literature search was conducted in PubMed, Scopus, and the Cochrane Library from database inception to 15 April 2026. Only randomized controlled trials (RCTs) were eligible. Data were extracted according to study design, participants’ characteristics, MSC source and dosing, safety outcomes, functional performance measures, quality of life (QoL) indices, and inflammatory, immune, and vascular biomarkers. Three RCTs met the inclusion criteria, comprising a total of approximately 208 participants. MSC administration was well-tolerated, with no treatment-related serious adverse events reported. Signals of improvement were reported in mobility-related and physical performance outcomes, although the magnitude and consistency of the response varied across studies. A dose-dependent increase in 6 min walk distance was observed at nine months in one trial, while improvements in SPPB, TUG, and grip strength were reported in the other studies. Additionally, MSC therapy was associated with QoL improvement and reduction in circulating pro-inflammatory cytokine concentrations. MSC administration was also associated with changes in immune-cell activation and a dose-dependent reduction in circulating sTIE2. Because of substantial clinical and methodological heterogeneity among the included trials, a quantitative meta-analysis was not performed. Current randomized evidence remains limited but suggests that intravenous MSC therapy is generally well tolerated in older adults with aging frailty and may produce clinically relevant signals of improvement in mobility-related functional outcomes, quality of life, and selected inflammatory, immune, and vascular biomarkers. However, the small number of trials, heterogeneity in MSC source, dose, endpoints, and follow-up duration, and the exploratory nature of much of the evidence preclude definitive conclusions regarding efficacy. Larger, adequately powered trials with standardized frailty endpoints are required, while future trials specifically targeting sarcopenia should apply consensus diagnostic criteria and direct measures of muscle quantity, strength, and physical performance.
- 25 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7596
Open AccessSafety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review
Aging frailty is a multifactorial geriatric syndrome characterized by reduced physiological reserve across multiple interrelated systems, leading to increased vulnerability to adverse health outcomes. Mesenchymal stem cells (MSCs) have emerged as a potential therapeutic intervention due to their immunomodulatory and regenerative properties. This systematic review aimed to evaluate the available clinical evidence regarding the safety and efficacy of MSC administration in individuals with aging frailty. A systematic literature search was conducted in PubMed, Scopus, and the Cochrane Library from database inception to 15 April 2026. Only randomized controlled trials (RCTs) were eligible. Data were extracted according to study design, participants’ characteristics, MSC source and dosing, safety outcomes, functional performance measures, quality of life (QoL) indices, and inflammatory, immune, and vascular biomarkers. Three RCTs met the inclusion criteria, comprising a total of approximately 208 participants. MSC administration was well-tolerated, with no treatment-related serious adverse events reported. Signals of improvement were reported in mobility-related and physical performance outcomes, although the magnitude and consistency of the response varied across studies. A dose-dependent increase in 6 min walk distance was observed at nine months in one trial, while improvements in SPPB, TUG, and grip strength were reported in the other studies. Additionally, MSC therapy was associated with QoL improvement and reduction in circulating pro-inflammatory cytokine concentrations. MSC administration was also associated with changes in immune-cell activation and a dose-dependent reduction in circulating sTIE2. Because of substantial clinical and methodological heterogeneity among the included trials, a quantitative meta-analysis was not performed. Current randomized evidence remains limited but suggests that intravenous MSC therapy is generally well tolerated in older adults with aging frailty and may produce clinically relevant signals of improvement in mobility-related functional outcomes, quality of life, and selected inflammatory, immune, and vascular biomarkers. However, the small number of trials, heterogeneity in MSC source, dose, endpoints, and follow-up duration, and the exploratory nature of much of the evidence preclude definitive conclusions regarding efficacy. Larger, adequately powered trials with standardized frailty endpoints are required, while future trials specifically targeting sarcopenia should apply consensus diagnostic criteria and direct measures of muscle quantity, strength, and physical performance.
- Open Access
- 18 July 2025
- Published by MDPI AG in Dentistry Journal
- Vol. 13 (7) , 328
Detection of Protein Carbonylation in Gingival Biopsies from Periodontitis Patients with or Without Diabetes Mellitus—A Pilot Study
Background: Protein carbonylation is an irreversible post-translational modification that is considered indicative of oxidative damage. Objective: The purpose of the study was to examine by an immunohistochemical method for the first time the extent and localization of protein carbonylation in biopsies of gingiva from periodontitis patients with or without diabetes mellitus (DM). Methods: These were processed for immunohistochemical staining of the carbonylated proteins, using the ENVISIOM FLEX Mini Kit, high pH, and anti-dinitrophenyl (DNP) antibody, a marker of oxidative damage to a given protein. The extent of protein carbonylation was semi-quantitatively estimated and evaluated by calculation of the Allred score (percentage of stained cells × intensity of staining). Results: The biopsies from periodontitis patients with diabetes mellitus (DM) exhibited higher staining scores as per the percentage of positively stained cells than the biopsies from patients with only periodontitis (means of 49.2 and 16.7, respectively), the difference being statistically significant (p = 0.036). The same trend was observed in the case of the combination of the above with the intensity of staining (score parameter) as well (means of 59.6 and 20.8, p = 0.036, respectively). Conclusions: An immunohistochemical method with the novelty of utilization for the first time of the anti-dinitrophenyl (DNP) antibody in gingival tissues was introduced and showed efficacy in detecting protein carbonylation indicative of oxidative stress and its impact in the pathogenesis of these two prevalent diseases of periodontitis and diabetes mellitus.
- 18 July 2025
- Published by MDPI AG in Dentistry Journal
- Vol. 13 (7) , 328
Open AccessDetection of Protein Carbonylation in Gingival Biopsies from Periodontitis Patients with or Without Diabetes Mellitus—A Pilot Study
Background: Protein carbonylation is an irreversible post-translational modification that is considered indicative of oxidative damage. Objective: The purpose of the study was to examine by an immunohistochemical method for the first time the extent and localization of protein carbonylation in biopsies of gingiva from periodontitis patients with or without diabetes mellitus (DM). Methods: These were processed for immunohistochemical staining of the carbonylated proteins, using the ENVISIOM FLEX Mini Kit, high pH, and anti-dinitrophenyl (DNP) antibody, a marker of oxidative damage to a given protein. The extent of protein carbonylation was semi-quantitatively estimated and evaluated by calculation of the Allred score (percentage of stained cells × intensity of staining). Results: The biopsies from periodontitis patients with diabetes mellitus (DM) exhibited higher staining scores as per the percentage of positively stained cells than the biopsies from patients with only periodontitis (means of 49.2 and 16.7, respectively), the difference being statistically significant (p = 0.036). The same trend was observed in the case of the combination of the above with the intensity of staining (score parameter) as well (means of 59.6 and 20.8, p = 0.036, respectively). Conclusions: An immunohistochemical method with the novelty of utilization for the first time of the anti-dinitrophenyl (DNP) antibody in gingival tissues was introduced and showed efficacy in detecting protein carbonylation indicative of oxidative stress and its impact in the pathogenesis of these two prevalent diseases of periodontitis and diabetes mellitus.
- Open Access
- 7 July 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (2) , 423-436
Early detection of kidney impairment in school-aged children born very preterm: a parallel use of traditional and modern biomarkers
Background: Prematurity has been linked to kidney dysfunction from infancy through adulthood. Children born very preterm are at particular risk due to interrupted nephrogenesis. However, early detection remains challenging, and a uniform monitoring strategy is lacking. Methods: This cross-sectional study involved school-aged (6–16 years) children born at ≤ 32 weeks of gestation, with no history of small for gestational age (SGA). They were further stratified by birth weight (BW): low, very low, and extremely low (LBW, VLBW, ELBW) categories. Age- and sex-matched full-term children served as controls. Anthropometry, blood pressure (BP), and kidney function were assessed, using traditional (urea; creatinine, Cr; β2-microglobulin, B2M; albuminuria) and modern biomarkers (cystatin C, CysC; symmetric dimethylarginine, SDMA). Estimated glomerular filtration rate (eGFR) based on Cr and Cr-CysC was also calculated. Statistical analysis was performed using R (version 4.3.2), with significance set at p < 0.05. Results: Eighty-one children were included: 43 preterm (77% from multiple pregnancies) and 38 controls. Compared to controls, preterm participants had higher serum cystatin C ( p < 0.001) and lower Cr-CysC-eGFR ( p < 0.001). They also had higher serum urea ( p = 0.002), but all individual values were within the normal range. No differences were observed in BP, serum Cr, Cr-eGFR, or albuminuria. ELBW children had lower body mass index (BMI) ( p = 0.048) and higher B2M ( p = 0.046) than LBW peers. Conclusions: School-aged children born very preterm may already exhibit subtle signs of kidney dysfunction, with ELBW children showing greater metabolic and renal strain. Cystatin C and Cr-CysC-eGFR appear promising biomarkers for early detection of kidney alterations in this high-risk population. Graphical
- 7 July 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (2) , 423-436
Open AccessEarly detection of kidney impairment in school-aged children born very preterm: a parallel use of traditional and modern biomarkers
Background: Prematurity has been linked to kidney dysfunction from infancy through adulthood. Children born very preterm are at particular risk due to interrupted nephrogenesis. However, early detection remains challenging, and a uniform monitoring strategy is lacking. Methods: This cross-sectional study involved school-aged (6–16 years) children born at ≤ 32 weeks of gestation, with no history of small for gestational age (SGA). They were further stratified by birth weight (BW): low, very low, and extremely low (LBW, VLBW, ELBW) categories. Age- and sex-matched full-term children served as controls. Anthropometry, blood pressure (BP), and kidney function were assessed, using traditional (urea; creatinine, Cr; β2-microglobulin, B2M; albuminuria) and modern biomarkers (cystatin C, CysC; symmetric dimethylarginine, SDMA). Estimated glomerular filtration rate (eGFR) based on Cr and Cr-CysC was also calculated. Statistical analysis was performed using R (version 4.3.2), with significance set at p < 0.05. Results: Eighty-one children were included: 43 preterm (77% from multiple pregnancies) and 38 controls. Compared to controls, preterm participants had higher serum cystatin C ( p < 0.001) and lower Cr-CysC-eGFR ( p < 0.001). They also had higher serum urea ( p = 0.002), but all individual values were within the normal range. No differences were observed in BP, serum Cr, Cr-eGFR, or albuminuria. ELBW children had lower body mass index (BMI) ( p = 0.048) and higher B2M ( p = 0.046) than LBW peers. Conclusions: School-aged children born very preterm may already exhibit subtle signs of kidney dysfunction, with ELBW children showing greater metabolic and renal strain. Cystatin C and Cr-CysC-eGFR appear promising biomarkers for early detection of kidney alterations in this high-risk population. Graphical
- Open Access
- 19 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1503
MSC1 Cells Suppress Colorectal Cancer Cell Growth via Metabolic Reprogramming, Laminin–Integrin Adhesion Signaling, Oxidative Stress Resistance, and a Tumor-Suppressive Secretome
Background/Objectives: Mesenchymal stem cells (MSCs) possess immunomodulatory properties, tumor-homing, and low immunogenicity, making them attractive for cell-based cancer therapies, but their role in colorectal cancer (CRC) remains controversial. The MSC1 phenotype, a pro-inflammatory, tumor-suppressive state induced by short-term, low-dose LPS activation via TLR4, has shown therapeutic promise but remains poorly characterized in CRC. We aimed to elucidate MSC1’s tumor-suppressive mechanisms and validate its activity against CRC cells using an integrated bioinformatics and in vitro approach. Methods: We constructed a high-confidence protein-protein interaction (PPI) network in Wharton’s jelly-derived MSCs (WJ-MSCs) following TLR4 activation to uncover enriched signaling pathways, transcriptional regulators, and secreted factors. Functional and transcriptional enrichment analyses pinpointed key mechanisms. We then co-cultured MSC1 cells with CRC cells to assess effects on proliferation and metabolism. Results: Network analysis revealed six tumor-suppressive mechanisms of MSC1 cells: (i) Metabolic reprogramming via enhanced glucose and lipid uptake, phosphoinositide signaling, and membrane/protein recycling, (ii) Robust antioxidant defenses, including SOS signaling and system xc⁻, (iii) Extracellular matrix stabilization and laminin-111–integrin-mediated adhesion, (iv) Secretome with direct anti-cancer effects, (v) Regulation of survival and cancer-associated fibroblasts (CAFs) formation inhibition through balanced proliferation, apoptosis, and epigenetic signals, (vi) Controlled pro-inflammatory signaling with anti-inflammatory feedback. In vitro, MSC1 cells significantly suppressed CRC cell proliferation and metabolic activity versus controls. Conclusions: This study provides the first mechanistic map of MSC1’s tumor-suppressive functions in CRC, extending beyond immunomodulation to include metabolic competition, ECM stabilization, and anti-cancer secretome activity. These findings establish MSC1 cells as a novel therapeutic strategy for CRC in cell-based cancer therapies.
- 19 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1503
Open AccessMSC1 Cells Suppress Colorectal Cancer Cell Growth via Metabolic Reprogramming, Laminin–Integrin Adhesion Signaling, Oxidative Stress Resistance, and a Tumor-Suppressive Secretome
Background/Objectives: Mesenchymal stem cells (MSCs) possess immunomodulatory properties, tumor-homing, and low immunogenicity, making them attractive for cell-based cancer therapies, but their role in colorectal cancer (CRC) remains controversial. The MSC1 phenotype, a pro-inflammatory, tumor-suppressive state induced by short-term, low-dose LPS activation via TLR4, has shown therapeutic promise but remains poorly characterized in CRC. We aimed to elucidate MSC1’s tumor-suppressive mechanisms and validate its activity against CRC cells using an integrated bioinformatics and in vitro approach. Methods: We constructed a high-confidence protein-protein interaction (PPI) network in Wharton’s jelly-derived MSCs (WJ-MSCs) following TLR4 activation to uncover enriched signaling pathways, transcriptional regulators, and secreted factors. Functional and transcriptional enrichment analyses pinpointed key mechanisms. We then co-cultured MSC1 cells with CRC cells to assess effects on proliferation and metabolism. Results: Network analysis revealed six tumor-suppressive mechanisms of MSC1 cells: (i) Metabolic reprogramming via enhanced glucose and lipid uptake, phosphoinositide signaling, and membrane/protein recycling, (ii) Robust antioxidant defenses, including SOS signaling and system xc⁻, (iii) Extracellular matrix stabilization and laminin-111–integrin-mediated adhesion, (iv) Secretome with direct anti-cancer effects, (v) Regulation of survival and cancer-associated fibroblasts (CAFs) formation inhibition through balanced proliferation, apoptosis, and epigenetic signals, (vi) Controlled pro-inflammatory signaling with anti-inflammatory feedback. In vitro, MSC1 cells significantly suppressed CRC cell proliferation and metabolic activity versus controls. Conclusions: This study provides the first mechanistic map of MSC1’s tumor-suppressive functions in CRC, extending beyond immunomodulation to include metabolic competition, ECM stabilization, and anti-cancer secretome activity. These findings establish MSC1 cells as a novel therapeutic strategy for CRC in cell-based cancer therapies.
- Open Access
- 26 May 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (1) , 61-72
Kidney health outcomes in children born very prematurely compared to full-term counterparts: a systematic review and meta-analysis
Background: Advances in neonatal care have improved survival rates in preterm neonates. However, concerns persist regarding the long-term kidney implications of prematurity. Nephrogenesis is disrupted, particularly in those born very preterm (≤ 32 weeks of gestation), increasing the risk of early kidney dysfunction and hypertension later in life. Objectives: This systematic review and meta-analysis aimed to evaluate kidney health outcomes in former very preterm children and adolescents compared to full-term peers. Data sources: A systematic literature search was conducted in MEDLINE/PubMed, Scopus, and Web of Science from their earliest available records to October 9, 2024. Study eligibility criteria: We included observational studies comparing kidney health parameters between children/adolescents born very preterm (gestational age – GA ≤ 32 weeks) and their full-term counterparts (gestational age > 36 weeks or birth weight > 2000 g) within the age range of 6 to 18 years. Participants and interventions: Children and adolescents aged 6–18 years born very preterm were compared to their full-term counterparts. The analyzed kidney function markers included serum Cystatin C, serum creatinine (sCr), estimated glomerular filtration rate (eGFR) based on sCr (Cr-eGFR), and blood pressure (systolic and diastolic, SBP/DBP). Study appraisal and synthesis methods: The Newcastle–Ottawa Scale was used to assess study quality. The mean difference with 95% confidence intervals was used for continuous outcomes. Statistical significance was set at p < 0.05. Sensitivity, subgroup and meta-regression analyses were conducted for further exploration of the outcomes. Statistical analyses were performed using R software (Version 4.3.2). Results: Thirteen studies (16 reports; 2,112 participants) were included. Very preterm children and adolescents had higher serum Cystatin C (0.05 mg/L; 95%CI: 0.02–0.08), lower Cr-eGFR (-11.87 mL/min/1.73 m 2 ; 95%CI: -22.44 to -1.31), and higher SBP (1.96 mmHg; 95%CI: 0.21–3.71). Sensitivity analysis confirmed Cystatin C findings but rendered Cr-eGFR and SBP differences non-significant. Subgroup analysis showed a significant GA effect on sCr ( p < 0.0001), though the ≥ 28 weeks subgroup included only two studies. Limitations: Considerable heterogeneity across studies persisted despite sensitivity and subgroup analyses. The lack of randomized controlled trials and longitudinal studies limits result interpretation, while non-significant meta-regression findings hinder full explanation of heterogeneity. Insufficient data prevented the assessment of additional kidney function parameters. Conclusions and implications of key findings: Cystatin C was elevated in very preterm individuals compared to full-term peers, reinforcing its role as an early marker of kidney dysfunction. While differences in Cr-eGFR and SBP lost significance after sensitivity analysis, these markers remain relevant for long-term follow-up in this vulnerable population. Systematic review registration number: PROSPERO (CRD42024554702). Graphical
- 26 May 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (1) , 61-72
Open AccessKidney health outcomes in children born very prematurely compared to full-term counterparts: a systematic review and meta-analysis
Background: Advances in neonatal care have improved survival rates in preterm neonates. However, concerns persist regarding the long-term kidney implications of prematurity. Nephrogenesis is disrupted, particularly in those born very preterm (≤ 32 weeks of gestation), increasing the risk of early kidney dysfunction and hypertension later in life. Objectives: This systematic review and meta-analysis aimed to evaluate kidney health outcomes in former very preterm children and adolescents compared to full-term peers. Data sources: A systematic literature search was conducted in MEDLINE/PubMed, Scopus, and Web of Science from their earliest available records to October 9, 2024. Study eligibility criteria: We included observational studies comparing kidney health parameters between children/adolescents born very preterm (gestational age – GA ≤ 32 weeks) and their full-term counterparts (gestational age > 36 weeks or birth weight > 2000 g) within the age range of 6 to 18 years. Participants and interventions: Children and adolescents aged 6–18 years born very preterm were compared to their full-term counterparts. The analyzed kidney function markers included serum Cystatin C, serum creatinine (sCr), estimated glomerular filtration rate (eGFR) based on sCr (Cr-eGFR), and blood pressure (systolic and diastolic, SBP/DBP). Study appraisal and synthesis methods: The Newcastle–Ottawa Scale was used to assess study quality. The mean difference with 95% confidence intervals was used for continuous outcomes. Statistical significance was set at p < 0.05. Sensitivity, subgroup and meta-regression analyses were conducted for further exploration of the outcomes. Statistical analyses were performed using R software (Version 4.3.2). Results: Thirteen studies (16 reports; 2,112 participants) were included. Very preterm children and adolescents had higher serum Cystatin C (0.05 mg/L; 95%CI: 0.02–0.08), lower Cr-eGFR (-11.87 mL/min/1.73 m 2 ; 95%CI: -22.44 to -1.31), and higher SBP (1.96 mmHg; 95%CI: 0.21–3.71). Sensitivity analysis confirmed Cystatin C findings but rendered Cr-eGFR and SBP differences non-significant. Subgroup analysis showed a significant GA effect on sCr ( p < 0.0001), though the ≥ 28 weeks subgroup included only two studies. Limitations: Considerable heterogeneity across studies persisted despite sensitivity and subgroup analyses. The lack of randomized controlled trials and longitudinal studies limits result interpretation, while non-significant meta-regression findings hinder full explanation of heterogeneity. Insufficient data prevented the assessment of additional kidney function parameters. Conclusions and implications of key findings: Cystatin C was elevated in very preterm individuals compared to full-term peers, reinforcing its role as an early marker of kidney dysfunction. While differences in Cr-eGFR and SBP lost significance after sensitivity analysis, these markers remain relevant for long-term follow-up in this vulnerable population. Systematic review registration number: PROSPERO (CRD42024554702). Graphical
- Open Access
- 17 March 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (3) , 427
Kinetics of Circulating Progenitor Cells and Chemotactic Factors in Full-Term Neonates with Encephalopathy: Indications of Participation in the Endogenous Regenerative Process
Preclinical studies have shown that progenitor cells (PCs) are mobilized toward injured tissues to ameliorate damage and contribute to regeneration. The exogenous therapeutic administration of PCs in children affected by neonatal encephalopathy (NE) is a promising, yet underreported, topic. In this prospective study, we investigated whether endogenous circulating progenitor cells (CPCs) are involved in intrinsic regeneration mechanisms following neonatal brain injury. Thirteen full-term infants with moderate/severe NE, eleven with perinatal stress, and twelve controls were enrolled. Blood samples were collected on days 1, 3, 9, 18, and 45, as well as at 8 and 24 months of life, and were analyzed with a focus on Endothelial Progenitor Cells, Haematopoietic Stem Cells, and Very Small Embryonic-Like Stem Cells, in addition to chemotactic factors (erythropoietin, IGF-1, and SDF-1). Correlations between CPCs, chemotactic factors, and brain injury were assessed using serum levels of brain injury biomarkers (S100B and neuron-specific enolase), brain MRIs, and Bayley III developmental scores. Increased brain injury biomarkers were followed by the upregulation of SDF-1 receptor and erythropoietin and, finally, by elevated CPCs. These findings suggest a potential endogenous regenerative effort, primarily observed in the moderate encephalopathy group, but this is suppressed in cases of severe brain injury. Mimicking and enhancing endogenous regeneration pathways in cases of failure—regarding cell type and timeframe—could provide a novel therapeutic model.
- 17 March 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (3) , 427
Open AccessKinetics of Circulating Progenitor Cells and Chemotactic Factors in Full-Term Neonates with Encephalopathy: Indications of Participation in the Endogenous Regenerative Process
Preclinical studies have shown that progenitor cells (PCs) are mobilized toward injured tissues to ameliorate damage and contribute to regeneration. The exogenous therapeutic administration of PCs in children affected by neonatal encephalopathy (NE) is a promising, yet underreported, topic. In this prospective study, we investigated whether endogenous circulating progenitor cells (CPCs) are involved in intrinsic regeneration mechanisms following neonatal brain injury. Thirteen full-term infants with moderate/severe NE, eleven with perinatal stress, and twelve controls were enrolled. Blood samples were collected on days 1, 3, 9, 18, and 45, as well as at 8 and 24 months of life, and were analyzed with a focus on Endothelial Progenitor Cells, Haematopoietic Stem Cells, and Very Small Embryonic-Like Stem Cells, in addition to chemotactic factors (erythropoietin, IGF-1, and SDF-1). Correlations between CPCs, chemotactic factors, and brain injury were assessed using serum levels of brain injury biomarkers (S100B and neuron-specific enolase), brain MRIs, and Bayley III developmental scores. Increased brain injury biomarkers were followed by the upregulation of SDF-1 receptor and erythropoietin and, finally, by elevated CPCs. These findings suggest a potential endogenous regenerative effort, primarily observed in the moderate encephalopathy group, but this is suppressed in cases of severe brain injury. Mimicking and enhancing endogenous regeneration pathways in cases of failure—regarding cell type and timeframe—could provide a novel therapeutic model.
- Open Access
- 20 November 2024
- Published by AccScience Publishing in Brain & Heart
- Vol. 2 (4) , 4521
The future of cardiac care: How stem cells are revolutionizing cardiovascular disease treatment
Cardiovascular diseases (CVDs) are a major global health issue, with current treatments often insufficient for addressing long-term cardiac damage. Stem cell therapy provides a promising alternative by potentially repairing damaged heart tissue and improving cardiac function. This review highlights recent advancements in stem cell applications for CVDs, focusing on heart tissue regeneration using various cell types, including mesenchymal stem cells and the newly discovered very small embryonic-like stem cells. Each cell type has unique characteristics that contribute to heart regeneration. Combining these cells with appropriate natural, synthetic, or decellularized scaffolds creates environments that better mimic the heart, resulting in improved outcomes. The clustered regularly interspaced short palindromic repeat/Cas9 gene editing technology advances these efforts by enabling precise genetic modifications. Despite these advancements, challenges such as cell culture variability, biomaterial selection, and clinical protocol standardization remain. Continued research and clinical trials are crucial to overcome these challenges and integrate stem cell therapies into standard cardiac care.
- 20 November 2024
- Published by AccScience Publishing in Brain & Heart
- Vol. 2 (4) , 4521
Open AccessThe future of cardiac care: How stem cells are revolutionizing cardiovascular disease treatment
Cardiovascular diseases (CVDs) are a major global health issue, with current treatments often insufficient for addressing long-term cardiac damage. Stem cell therapy provides a promising alternative by potentially repairing damaged heart tissue and improving cardiac function. This review highlights recent advancements in stem cell applications for CVDs, focusing on heart tissue regeneration using various cell types, including mesenchymal stem cells and the newly discovered very small embryonic-like stem cells. Each cell type has unique characteristics that contribute to heart regeneration. Combining these cells with appropriate natural, synthetic, or decellularized scaffolds creates environments that better mimic the heart, resulting in improved outcomes. The clustered regularly interspaced short palindromic repeat/Cas9 gene editing technology advances these efforts by enabling precise genetic modifications. Despite these advancements, challenges such as cell culture variability, biomaterial selection, and clinical protocol standardization remain. Continued research and clinical trials are crucial to overcome these challenges and integrate stem cell therapies into standard cardiac care.
- Open Access
The “Forgotten” Hydroxyapatite Crystals in Regenerative Bone Tissue Engineering: A Critical Review
Bone regeneration using Bone Morphogenetic Proteins (BMPs) alongside various engineered scaffolds has attracted considerable attention over the years. The field has seen extensive research in preclinical animal models, leading to the approval of two products and guiding the quest for new materials. Natural and synthetic polymers, ceramics, and composites have been used to fabricate the necessary porous 3D scaffolds and delivery systems for BMPs. Interestingly, all reported applications in the literature are triumphant. Evaluation of the results is typically based on histologic assessment after appropriate staining and radiological modalities, providing morphological identification of the newly formed bone and describing cells and the organic compound. Remarkably, while these evaluation methods illustrate mineralization, they are not capable of identifying hydroxyapatite crystals, the mineral component of the bone, which are crucial for its mechanical properties, structure, integrity, and long-term stability of regenerated bone tissue. This review aims to focus on the different scaffolds used in bone tissue engineering applications and underline the pressing need for techniques that could recognize the presence of hydroxyapatite crystals as well as their characteristics in bone tissue engineering, which will provide a more complete and comprehensive assessment of the successful results.
Open AccessThe “Forgotten” Hydroxyapatite Crystals in Regenerative Bone Tissue Engineering: A Critical Review
Bone regeneration using Bone Morphogenetic Proteins (BMPs) alongside various engineered scaffolds has attracted considerable attention over the years. The field has seen extensive research in preclinical animal models, leading to the approval of two products and guiding the quest for new materials. Natural and synthetic polymers, ceramics, and composites have been used to fabricate the necessary porous 3D scaffolds and delivery systems for BMPs. Interestingly, all reported applications in the literature are triumphant. Evaluation of the results is typically based on histologic assessment after appropriate staining and radiological modalities, providing morphological identification of the newly formed bone and describing cells and the organic compound. Remarkably, while these evaluation methods illustrate mineralization, they are not capable of identifying hydroxyapatite crystals, the mineral component of the bone, which are crucial for its mechanical properties, structure, integrity, and long-term stability of regenerated bone tissue. This review aims to focus on the different scaffolds used in bone tissue engineering applications and underline the pressing need for techniques that could recognize the presence of hydroxyapatite crystals as well as their characteristics in bone tissue engineering, which will provide a more complete and comprehensive assessment of the successful results.